CN
Cmail Search Menu
Home|News

2023/11/11

Shandong Xinbo supports the clinical application of the combination of human monoclonal antibodies A82/B86 against tetanus toxin for injection

On October 30, 2023, Changchun Baike Biotechnology Co., Ltd...
More
热烈祝贺山东欣博药物研究有限公司成功举办第三届“精益求精”杯排球联赛

2023/11/11

Warm congratulations to Shandong Xinbo Pharmaceutical Research Co., Ltd. for successfully hosting the 3rd "Striving for Excellence" Cup Volleyball League

To enrich the sports and cultural life of employees, strengthen the cohesion and teamwork ability of the company, stimulate employees' enthusiasm for participating in company activities, and create a united, active, and progressive corporate atmosphere...
山东欣博举行升国旗仪式

2023/10/11

Shandong Xinbo held a flag raising ceremony

On October 10, 2023, Shandong Xinbo Pharmaceutical Research Co., Ltd. held a flag raising ceremony....
山东欣博助力世界首个PLpro小分子抑制剂获批临床

2023/09/22

Shandong Xinbo supports the approval of the world's first PLpro small molecule inhibitor for clinical use

On August 29, 2023, a team led by He Wei from the School of Pharmacy at Tsinghua University, in collaboration with the Land Transport Team from the School of Basic Medicine at Fudan University, conducted research and development...
山东欣博助力肠道病毒71型-柯萨奇病毒A16型灭活疫苗(人二倍体细胞)获批开展临床

2023/09/22

Shandong Xinbo supports the approval of clinical trials for the inactivated vaccine of enterovirus 71 Coxsackievirus A16 (human diploid cell)

In September 2023, the Institute of Medical Biology, Chinese Academy of Medical Sciences independently developed an enterovirus...
山东欣博刘宝峰技术副总受邀参加中药研发注册法规要求暨申报实践培训班

2023/06/27

Shandong Xinbo Liu Baofeng, Vice President of Technology, was invited to participate in the training course on regulatory requirements and application practices for traditional Chinese medicine resear

Shandong Xinbo Liu Baofeng, Vice President of Technology, was invited to participate in the training course on regulatory requirements and application practices for traditional Chinese medicine research and development registration...
喜报 | 山东欣博获得第二届医疗器械植入后反应实验室间比对活动“满意”证书

2023/06/13

Good news | Shandong Xinbo has obtained the "Satisfaction" certificate for the second inter laboratory comparison activity of post implantation reactions of medical devices

On June 9, 2023, Shandong Xinbo Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Shandong Xinbo") participated in the second inter laboratory comparison activity for post implantation reactions of medical devices....
山东欣博药物研究有限公司举行升旗仪式

2023/05/03

Shandong Xinbo Pharmaceutical Research Co., Ltd. held a flag raising ceremony

On the morning of May 2, 2023, Shandong Xinbo Pharmaceutical Research Co., Ltd. held its first flag raising ceremony in front of the scenic stone in the park to pay tribute to workers, promote patriotism, and inspire and strengthen all employees....
山东欣博助力国内首款三靶点DNA肿瘤疫苗-NMM肿瘤治疗性DNA疫苗裸质粒注射液获得临床试验许可

2023/04/07

Shandong Xinbo Helps China's First Three Target DNA Tumor Vaccine - NMM Tumor Therapeutic DNA Vaccine Naked Plasmid Injection Obtain Clinical Trial License

Recently, Gu'an Dingtai Haigui Biotechnology Co., Ltd. developed a Class 1 new drug - the NMM tumor therapeutic DNA vaccine naked plasmid injection...
山东欣博助力百克生物1类新药天然全人源抗狂犬病毒单克隆抗体CBB1注射液获得临床试验许可

2023/03/15

Shandong Xinbo assists Baike Biotechnology in obtaining clinical trial approval for its Class 1 new drug, CBB1 injection, a natural all human monoclonal antibody against rabies virus

Recently, Changchun Baike Biotechnology Co., Ltd.'s Class 1 new drug - natural all human monoclonal antibody CBB1 injection against rabies virus - has been approved by the National Medical Products Administration (NMPA) of China....
上一页 1234567 下一页

Did you find the information you needed?

Great, thank you for your feedback.
Thank you for your feedback.